Form 4: Simulations Plus Director Sells Shares Under 10b5-1 Plan
Insider Transaction Disclosure
Simulations Plus, Inc. Director Lisa LaVange sold 866 shares of common stock at $16.91 per share through a pre-arranged Rule 10b5-1 trading plan.
Summary
- Lisa LaVange, a Director of Simulations Plus, Inc. (SLP), reported a sale of common stock.
- The transaction involved the disposition of 866 shares of common stock.
- The shares were sold at a price of $16.91 per share.
- The sale was executed on December 1, 2025.
- Following this transaction, Lisa LaVange beneficially owns 9,968 shares of Simulations Plus, Inc. common stock directly.
- The sale was conducted automatically pursuant to a Rule 10b5-1 plan adopted by the reporting person.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction under a pre-arranged 10b5-1 plan, which is a neutral event and does not inherently convey positive or negative sentiment about the company's performance or future prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This Form 4 filing details a routine insider transaction for Simulations Plus, Inc., a company operating in the pharmaceutical and biotechnology software and services industry. Such transactions are common for corporate directors and executives, particularly when executed under pre-arranged 10b5-1 plans, and do not inherently reflect broader industry trends or competitive positioning.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Compliance | The reported sale was effected automatically pursuant to a Rule 10b5-1 plan, which is a pre-arranged trading plan designed to allow insiders to sell company stock without being accused of trading on material non-public information. This demonstrates adherence to corporate governance best practices regarding insider trading. | 12/01/2025 | Enhances transparency and mitigates potential concerns regarding insider trading, aligning with regulatory compliance standards. |
Stakeholder Impact
- Shareholders: A routine insider sale under a 10b5-1 plan typically has minimal impact on shareholder sentiment, as it is a pre-scheduled event rather than a discretionary sale based on new information.
Key Dates
| Date | Description |
|---|---|
| 12/01/2025 | Date of transaction (sale of common stock) |
| 12/02/2025 | Date of Form 4 filing |
Keywords
Simulations Plus, SLP, Insider Trading, Form 4, Stock Sale, Director Transaction, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.